Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor
about
Single Nucleotide Polymorphisms in Cellular Drug Transporters Are Associated with Intolerance to Antiretroviral Therapy in Brazilian HIV-1 Positive IndividualsKnocking down breast cancer resistance protein (Bcrp) by adenoviral vector-mediated RNA interference (RNAi) in sandwich-cultured rat hepatocytes: a novel tool to assess the contribution of Bcrp to drug biliary excretionMontelukast is a potent and durable inhibitor of multidrug resistance protein 2-mediated efflux of taxol and saquinavirConcentration-dependent effects and intracellular accumulation of HIV protease inhibitors in cultured CD4 T cells and primary human lymphocytes.Differential effect of P-gp and MRP2 on cellular translocation of gemifloxacinIntracellular accumulation of Praziquantel in T lymphoblastoid cell lines, CEM (parental) and CEMVBL(P-gp-overexpressing).Drug-transporter mediated interactions between anthelminthic and antiretroviral drugs across the Caco-2 cell monolayers.Influence of overexpression of efflux proteins on the function and gene expression of endogenous peptide transporters in MDR-transfected MDCKII cell lines.From fighting depression to conquering tumors: a novel tricyclic thiazepine compound as a tubulin polymerization inhibitorMRP (ABCC) transporters-mediated efflux of anti-HIV drugs, saquinavir and zidovudine, from human endothelial cells.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Functional role of p-glycoprotein and binding protein effect on the placental transfer of lopinavir/ritonavir in the ex vivo human perfusion modelAmino Acid Prodrugs: An Approach to Improve the Absorption of HIV-1 Protease Inhibitor, LopinavirInteraction of ocular hypotensive agents (PGF2 alpha analogs-bimatoprost, latanoprost, and travoprost) with MDR efflux pumps on the rabbit cornea.Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroidsPeptide prodrugs: improved oral absorption of lopinavir, a HIV protease inhibitor.Effects of HIV-1 Tat and Methamphetamine on Blood-Brain Barrier Integrity and Function In Vitro.Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.Differences in genetic variants in lopinavir disposition among HIV-infected Bantu Africans.Cultured CD4T cells and primary human lymphocytes express hOATPs: intracellular accumulation of saquinavir and lopinavir.Expression Profile of Drug and Nutrient Absorption Related Genes in Madin-Darby Canine Kidney (MDCK) Cells Grown under Differentiation Conditions.Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir.Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients.Surface-stabilized lopinavir nanoparticles enhance oral bioavailability without coadministration of ritonavir.The Role of PXR Genotype and Transporter Expression in the Placental Transport of Lopinavir in Mice.Steady-state plasma concentration of donepezil enantiomers and its stereoselective metabolism and transport in vitro.
P2860
Q28554250-8178BD07-A159-4F8D-9F27-602677C1000FQ28570070-36586922-D613-4D0F-852E-5A68537EF1A8Q33611816-2DE5C1BC-A73E-4E0A-BBD5-1CE32FACE95BQ33776536-3AE7EC6C-00F7-4065-9E9F-E3E22F181E0BQ35374935-7F972E2A-2E1D-470E-8DC0-C58369393BDEQ36103626-95A23C1F-B0F4-41CC-95AA-A8C9E7B185C6Q36362462-A94AA30A-B15C-4A01-A05F-01EB3B2C757CQ36744766-1E08CF91-1A43-4E4D-99B4-A2B5B8C4A904Q36775000-77C11BD6-6950-4301-B330-24780F330E4BQ36953719-6258D4F2-8E15-4172-9135-D894C56A8BF8Q37113947-4DABECB9-A30D-400D-8AD5-EECAB223F169Q37423787-93A7215C-B56E-46A3-8754-649D07D5DACBQ39395865-3AA98AE4-E71E-487C-B134-E8956B9F39D2Q39760193-A9A6997B-AF84-4D94-B7F6-8AD47B6DE046Q39900651-CFC4BEBE-486C-4F8A-B477-D1608F76F85EQ39923954-EB7F57AB-2E7C-4346-B53A-ABF60C014A76Q39985490-4D93FD32-F654-4AD3-9286-90CD9CD3882BQ40052643-1CB7ACFB-B7EF-47B8-85DD-63CB3D02B471Q40500118-769ED259-3B95-4EB1-8F0A-B7252E49BB16Q40688836-477188A3-82A8-4A3C-AB6B-4FA63AF01FB4Q41139969-A213EBD8-8224-458A-A0D1-2FE8EA075E5DQ41855448-3EE07681-5459-405C-AB18-8B893A92BC2FQ42429561-7C056B6C-09E3-4FF4-B3C7-B6C83C7E18C9Q43168123-DFA33EDA-D9C6-4C2B-837E-4ACA58EA9CF9Q43258274-04C326FF-399C-4E99-AF06-6EBD508424D7Q45722674-D0ED03D0-8FC9-4655-B769-9979A06AA12EQ47397797-78BCDEAE-B096-4C74-B454-9D33D7E4EB25Q53341299-6A892425-FAF4-41F4-8938-6757CF1E7723
P2860
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor
description
2007 nî lūn-bûn
@nan
2007 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի մարտին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor
@ast
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor
@en
type
label
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor
@ast
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor
@en
prefLabel
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor
@ast
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor
@en
P2093
P2860
P1476
Both P-gp and MRP2 mediate transport of Lopinavir, a protease inhibitor
@en
P2093
Ashim K Mitra
Dhananjay Pal
Sheetal Agarwal
P2860
P304
P356
10.1016/J.IJPHARM.2007.02.036
P407
P577
2007-03-06T00:00:00Z